← 返回

骨肉瘤中的新兴免疫疗法:从检查点阻断到细胞疗法

英文原题:Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies.

查看英文原题

Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies.

PubMed 2025/03/18(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

骨肉瘤仍然是一种高度侵袭性的骨恶性肿瘤,治疗选择有限,亟需新的治疗策略。免疫治疗已成为一种有前景的方法,但其在骨肉瘤中的疗效受到免疫抑制性肿瘤微环境和耐药机制的限制。本综述探讨了检查点阻断、细胞治疗以及旨在增强免疫反应的联合策略方面的最新进展。我们强调了关键挑战,包括肿瘤异质性、免疫浸润不良以及预测性生物标志物的需求。通过将免疫治疗与化疗、放疗和靶向治疗相结合,新兴方法旨在改善治疗结局。本综述对骨肉瘤免疫治疗不断演变的格局进行了全面分析,为未来方向和潜在突破提供了见解。研究人员和临床医生将受益于对这些进展的理解,因为它们为骨肉瘤更有效和个性化的治疗策略铺平了道路。

展开英文摘要原文

Osteosarcoma remains a highly aggressive bone malignancy with limited therapeutic options, necessitating novel treatment strategies. Immunotherapy has emerged as a promising approach, yet its efficacy in osteosarcoma is hindered by an immunosuppressive tumor microenvironment and resistance mechanisms. This review explores recent advancements in checkpoint blockade, cellular therapies, and combination strategies aimed at enhancing immune responses.

We highlight key challenges, including tumor heterogeneity, poor immune infiltration, and the need for predictive biomarkers. By integrating immunotherapy with chemotherapy, radiotherapy, and targeted therapy, emerging approaches seek to improve treatment outcomes.

This review provides a comprehensive analysis of the evolving landscape of osteosarcoma immunotherapy, offering insights into future directions and potential breakthroughs. Researchers and clinicians will benefit from understanding these developments, as they pave the way for more effective and personalized therapeutic strategies in osteosarcoma.

论文信息

作者
Han Z、Chen G、Wang D
单位
Department of Orthopedics, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.China
文献类型
综述
期刊
Frontiers in immunology2025
原文标识
PubMed 40170852 · DOI 10.3389/fimmu.2025.1579822